Pre-exposure prophylaxis use among HIV serodiscordant couples: a qualitative study in Mozambique

Daniel E. Sack a,*, Caroline De Schacht b, Paula Paulo c, Erin Graves c, Almio M. Emilio c, Ariano Matino c, Carlota L. Fonseca c, Arifo U. Aboobacar c, Sara Van Rompaey b and Carolyn M. Audet a

aVanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN, USA; bFriends in Global Health, Maputo, Mozambique; cFriends in Global Health, Quelimane, Mozambique

ABSTRACT
Background: Pre-exposure prophylaxis (PrEP) has the potential to reduce HIV transmission and stem the HIV epidemic. Unfortunately, PrEP uptake in rural sub-Saharan Africa has been slow and medication adherence has been suboptimal.
Objective: To explore the perspectives, attitudes, and experiences of HIV serodiscordant partners taking PrEP and develop a messaging campaign to improve PrEP uptake in rural Mozambique to reduce HIV transmission among serodiscordant partners.
Methods: In this qualitative study, we interviewed 20 people in serodiscordant relationships using PrEP at a rural health center in Zambézia province, Mozambique and employed inductive and deductive coding to elicit their perspectives, attitudes, and experiences related to learning their partner’s HIV status, barriers to PrEP uptake, obstacles to PrEP adherence, and decisions to disclose their PrEP use with family and friends using thematic analysis.
Results: Our analysis generated nine themes across various levels of the socioecological model. Participants reported a strong desire to stay in the discordant relationship and highlighted the importance of working together to ensure PrEP and antiretroviral therapy adherence, with the majority skeptical that adherence could be achieved without both partners’ support (individual and interpersonal). Although most participants were reticent about sharing their serodiscordant status with family and friends (individual and interpersonal), those who did found their family and friends supportive (interpersonal). Participants suggested increasing community health agent availability to help people navigate HIV prevention and treatment (organizational). We then created three oral stories, using themes from the interviews, with examples from various levels of the socioecological model that will be used to generate support for PrEP use among community members.
Conclusions: Our findings informed oral template stories that will be used to emphasize how couples can work together to improve PrEP uptake and reduce incident HIV infections in serodiscordant couples elsewhere in rural Mozambique.

BACKGROUND
Pre-exposure prophylaxis (PrEP) uptake and retention is key to reducing HIV transmission and the global burden of HIV [1–5]. Low medication adherence in initial clinical trials made it difficult to assess PrEP’s ability to prevent HIV transmission to women in serodiscordant relationships living in sub-Saharan Africa [6–11]. Although HIV transmission within serodiscordant couples, which accounts for 5–53% of HIV transmission in the region, occurs at a rate of approximately 11.1 per 100 person-years in sub-Saharan Africa, people in serodiscordant relationships report several barriers to PrEP uptake and adherence [12–15]. These obstacles include discomfort discussing PrEP/ART, a lack of knowledge about PrEP, and confusion navigating sexual encounters (e.g. condom use with primary partners) [14,15]. Serodiscordant couples also report that their fear of contracting HIV and stigma related to leaving their partner makes it difficult to stay in the relationship (particularly for women with a seropositive partner) [14,15].
PrEP implementation challenges in sub-Saharan Africa have been attributed to medication regulatory requirements, cost effectiveness concerns, a lack of health system capacity, HIV stigma, and medication adherence and efficacy concerns [16,17]. In 2018, PrEP became available for people in serodiscordant relationships at district level health facilities in Zambézia province, Mozambique [18]. Zambézia is a rural, north-central province with approximately 5.1 million people, with some of the lowest health and development indicators in Mozambique [19–21]. Its HIV prevalence, approximately 15%, is among the highest in the country, 30% of people living with HIV are on ART, and 49.5% of people on ART are virally suppressed (23.1% of all people living with HIV) [19].
Although healthcare providers were aware of clinical guidelines for PrEP management, among the few thousand individuals who initiated PrEP, about half stopped taking it after 2–6 months and misunderstandings about and stigma related to PrEP persisted among those at risk for HIV during the initial rollout [18].

In this qualitative study we assessed attitudes and perceptions about PrEP use in people in serodiscordant relationships who had initiated PrEP at a district health facility in Zambézia. After analyzing participant responses, we developed three oral stories designed to educate, empower, and normalize PrEP use. These stories will be presented to discordant couples to try improve PrEP uptake and reduce incident HIV infections in rural Mozambique.

**Methods**

**Study design**

This cross-sectional, qualitative study employed thematic analysis to analyze in-depth interviews and develop oral stories intended to improve PrEP uptake in rural Mozambique.

**Participant sampling**

We approached all adults (≥18 years old) who reported they were HIV-negative, in a serodiscordant relationship, and had ever taken or were currently taking PrEP between 28 November 2019 to 24 January 2020 at a primary care clinic in Namacurra, Mozambique due to the availability of study personnel at the clinic. Nurses at the clinic informed patients using PrEP of the study and referred those who expressed interest to a research assistant to assess eligibility. We recruited participants until we reached data saturation [22]. Of the 22 patients referred to study personnel, 20 were eligible and agreed to participate.

**Data collection**

Between November 2019 and January 2020, we conducted 20 semi-structured in-depth interviews (Table 1). Fieldworkers had more than ten years of experience conducting qualitative interviews in Zambézia Province and received a five-day refresher training course in qualitative interview methods, including time to craft and improve our interview guide, originally developed based on our experience working in the area, before data collection began (Table 1). Interview training included sessions on developing rapport (e.g. introducing themselves, using colloquial phrasing, establishing eye contact, asking follow-up questions, and interviewing in a private location) and establishing trustworthiness (e.g. explaining the study’s purpose, describing data storage and access systems to ensure privacy, responding to the participants’ questions). Interviews included member checking, where fieldworkers summarized important details to ensure they accurately understood participants’ opinions and experiences. Fieldworkers also employed an iterative approach to add additional questions/probes based on previous respondents’ feedback. Interviews lasted 20–50 minutes, were conducted one-on-one in Portuguese (8) or Ecuabo (12), and took place at the clinic or another meeting place at the convenience of the interviewee. Interviews were audio-recorded and all interviews, with one exception, were transcribed, translated into Portuguese if conducted in Ecuabo, and then verified. We excluded one interview from our analysis because we could not verify the quality of the transcription after the audio was accidentally deleted after the first transcription. Two researchers translated the 19 remaining interviews from Portuguese into English for analysis.

**Data analysis**

Researchers DES and CMA reviewed the English transcripts and conducted thematic analysis with MAXQDA20© software. Researchers DES and CMA first familiarized themselves with the data by doing three read throughs of each interview and taking notes about initial comments relevant to PrEP uptake. Subsequently, we developed the initial codes deductively, guided by the socioecological model and previous research about barriers to and facilitators of PrEP adherence [17,23,24]. The socioecological model classifies themes or interventions as impacting the individual, interpersonal, organizational, or community level of influence/change and provides a useful framework for thinking about interventions that aim to prevent HIV transmission given the complex sociocultural drivers of the HIV epidemic [23–25]. In vivo (inductive) codes were generated when unique barriers to and facilitators of PrEP adherence were identified on repeated reading. We identified patterns among our codes, interpreting their broader significance employing the individual, interpersonal, organizational/clinic, and community levels of the socioecological model [23]. Over five meetings, DES and CMA met to develop, define, and compare their coding, after which there was complete agreement in the application of deductive and inductive codes and sub-codes. Codes where then assigned to overarching themes [26].

**Oral story development**

We subsequently incorporated common themes relevant to support PrEP uptake and adherence into three oral stories that will be used to educate
community members about PrEP, generate family member support for the discordant couple, and de-stigmatize PrEP use. The stories integrate into Mozambique’s rich history of oral storytelling [27–29]. We used the socioecological model and our understanding of how it’s used in the HIV prevention literature to guide how we structured our stories [23,25]. While we focused on including individual and interpersonal factors as facilitators of PrEP uptake within serodiscordant couples, we also provided examples of how couples could leverage organizational and community-level support [23].

Results

Among the 19 participants (median age 35, interquartile range 26.5–37.5) included in analysis, 11 were female (median age 32, interquartile range 25.5–36) and 8 were male (median age 36, interquartile range 31–38). We identified 26 sub-codes across interviews, which fit into nine themes organized within levels of the socioecological model (Figure 1). These included three individual level themes – 1) love for one’s partner, 2) knowledge that PrEP exists and is effective, 3) fear of HIV and PrEP stigma – four interpersonal level themes – 4) desire to protect family, 5) partner support and relationship strength, 6) support from family and friends, 7) gendered adherence approaches – and two organizational level themes – 8) welcoming clinicians, and 9) supportive community health workers. We have mostly framed our themes as positive because we are developing stories intended to present strategies and examples of effective PrEP use. Love for one’s partner, for example, highlights how a strong relationship increases PrEP uptake; however, a lack of love within a relationship signals a barrier to PrEP uptake. Other themes, however, contain both positive and negative influences on behavior (e.g. gendered uptake and adherence approaches) or are entirely negative (e.g. fear of PrEP and HIV stigma). The themes highlight how participants reacted to their partner’s HIV diagnosis, how couples worked together to adhere to their medicines, with whom and why they did or did not discuss PrEP, and participant suggestions for future interventions. Using the socioecological model, we then describe the key characteristics of the three oral stories we created based on participant responses (Table 2).

Table 1. Qualitative interview guide.

|   |   |   |
|---|---|---|
| 1. | How did you react to finding out you were HIV-negative and your partner was HIV-positive? (probe: did you consider leaving the relationship? What emotions/thoughts came up for you, or both of you together?) |   |
| 2. | Did you tell any other people about the results you learned? If so, what were the reactions of people you told? |   |
| 3. | Tell me what you were told about PrEP from the nurse/health care provider? What were the concerns you had about it? What benefits did you see in taking it? What influenced your decision to start taking it? |   |
| 4. | Did you tell your partner that you were taking PrEP? What was his/her reaction? How did their reaction make you feel? |   |
| 5. | How do you or did you feel about taking the medication? Do you or did you take the medication regularly as it was prescribed? If you are taking it intermittently, what information would help you be more adherent to your medication? |   |
| 6. | Has anyone in your family known that you are or were taking PrEP medication? How have they reacted to this? If you have stopped taking the medication, do you think having a more supportive family member(s) would have helped you be more adherent to your medication (i.e. stay on PrEP medication longer)? |   |
| 7. | People often learn more from stories than from listening to facts. We were thinking about offering people information about PrEP through storytelling. Imagine these three different situations: |   |
| a. | A couple who struggles to overcome the difficulties associated with having a different HIV status compared to their partner. Specifically, the woman accuses the man of cheating on her and she is frustrated that she now has to take PrEP medication. Mostly she is scared that she will get HIV. What is the best way for the couple to stay together and be supportive of each other’s health? |   |
| b. | A woman has an HIV-positive partner who refuses to take ART medication and doesn’t support her taking PrEP. She chooses to take her medication in secret and attend clinic visits in secret as well. Do you think a woman could manage this? What would be the best way to support her? (e.g. other family? Friends? Health care workers? Educate her partner?) |   |
| c. | A serodiscordant couple is very supportive of each other. They help each other remember to take their medications and help out with chores when one isn’t feeling well. The problem is that the extended family is not supportive of them staying together or the woman taking PrEP. They are rude to both the partners and spread rumors about them. How can a couple best manage this type of situation? What would be the best way to support them? |   |

Italicized text indicates question probes or scenarios that precede questions

PrEP: Pre-Exposure Prophylaxis

Individual factors influencing PrEP uptake and adherence

Love for one’s partner

Although participants were largely motivated by the concern for their own health and that of their children, many noted that their love and affection for their partner could help overcome challenges accompanying living in a discordant relationship. Four participants spoke about love as their motivation to remain adherent to medication. One woman explained:

… where there is love, no one can destroy. It is up to these two if in fact they have to reach this point of consensus because they talked, they saw that it seems
that life is still going on, so we will continue, we will be doing this treatment. No listening to this one or that one who comes with advice, but it is up to us (female, 38).

Only one 29-year-old female participant reported feeling anger towards her partner when she learned his HIV diagnosis. She reported feeling betrayed because her partner’s diagnosis exposed his continued extra-marital affairs. She was irritated that, ‘his health situation … forced me to take these drugs’ (female, 29). Despite these feelings, she stayed with her partner and continued to take PrEP for more than a year.

Knowledge about PrEP and the belief it is effective
Participants reported low levels of knowledge about PrEP before receiving a discordant diagnosis. The limited efforts to educate community members about PrEP, which has led to low demand for the medication (a substantial barrier to uptake), have also decreased misconceptions or conspiracy theories like those that surround HIV medication. Nurse-led education about and access to PrEP enabled couples to feel comfortable with their decision to stay together. One participant elaborated, ‘I didn’t even know that there was a PrEP treatment so for both of us it was a great victory to know that he will be much better, and I will be protected from the HIV virus’ (female, 37). One woman even expressed relief at finally having a diagnosis,

… we were already tired going to several great people (traditional medicine practitioners), but it didn’t get better, and it got worse. That was when he decided to come to the hospital to do the test. Everyone is taking their medication and we are fine (female, 25).

Fear of HIV and PrEP stigma
While PrEP itself was not well-known, HIV remained highly stigmatized. Many participants feared stigma if other members of their family or friends were to find out that their partner was HIV-positive or that they were taking PrEP. One participant reported, ‘ … in the community people react in strange ways to people who are living with HIV … That’s why we don’t tell anyone about our situation’ (male, 32). Few disclosed their status to more than one or two family members.

A few participants expressed their anticipated stigma as a fear of witchcraft or curses from community members. One woman commented, ‘if people know about your condition, they can increase your disease with a spell to make people think it is HIV’ (female, 38). Another woman commented that, ‘[If I say] that my husband has HIV, other people can take advantage and cast witchcraft on us’ (female, 26).

Interpersonal factors affecting PrEP uptake
Desire to protect family
Both men and women spoke about the importance of adherence, particularly to ensure the wellbeing of their children. One man noted that his ‘concern at the moment was if I was taking these drugs myself, I would not get the disease that my wife has, and our children end up suffering from the disease that both parents have’ (male, 32). Although almost all participants reported feeling sad about their partner’s HIV diagnosis, they were not angry, nor did they threaten to leave. One participant explained,

I had this thought: she didn’t want it [HIV]. I didn’t want it either. It is God’s destiny. If I had the idea of
### Table 2. Oral story framework.

| Situation | Facilitators of PrEP Use | Barriers to PrEP Use | Strategies to Overcome Barriers |
|-----------|--------------------------|----------------------|-------------------------------|
| 1. A Positive Story | Partners are screened for HIV at a postnatal visit for their fourth child and the male partner tests positive while his female partner tests negative | - The couple loves each other  
- They want to be there for their children and new baby  
- The couple listens to each other’s fears  
- They encourage each other to adhere to their medications | - Lack of knowledge about the purpose of PrEP  
- Fear about how others in their community may react to learning that the male partner has HIV | - They brought their questions to a health counsellor at the clinic  
- They decide to keep their serodiscordant status to themselves to avoid stigma from their community |
| 2. An Unsupportive Family | Partners are screened for HIV at the first prenatal care visit for their first child and the male partner tests positive while his female partner tests negative | - The couple was tested together and received counselling together  
- The couple want to keep themselves and their child healthy | - The female partner is worried that her partner’s diagnosis means he was unfaithful  
- They are scared to tell their family, as they are concerned that they will be judged for staying together  
- Their family finds their medications and is upset and makes accusations | - The clinic health counsellor explains the different ways that HIV can spread  
- The couple engaged with a Peer Educator, who helped facilitate a conversation with the couple’s family, who then became supportive |
| 3. A ‘Difficult’ Partner | Partners are screened for HIV at a prenatal care visit for their third child and the male partner tests positive while his female partner tests negative | - The couple knew about PrEP from a neighbour and were initially interested | - The male partner is angry about his diagnosis and the side effects from his ART and does not want to take them | - The female partner requests assistance from the Peer Educator to help her male partner understand how taking his medications will protect his family and educate him about how long to expect the medication side effects to last  
- The partners work together to remind each other to take their medications |

PrEP: Pre-Exposure Prophylaxis  
ART: Antiretroviral Therapy

---

GLOBAL HEALTH ACTION
leaving her, I can find something worse out there, so I preferred to stay with her (male, 35).

**Partner support and relationship strength**

Most participants reported working with their partner to improve ART and PrEP uptake and adherence. Few believed that someone could manage to take PrEP without the support of their partner. One, in response to a story designed to elicit an opinion about a woman using PrEP without her partner’s knowledge, said,

I don’t think she will make it. She will take it for a while, but then she will give up because it will not be possible for both of them in the same house … to keep this secret for a long time. I think this woman will not even reach a year to take the medication because they are in disagreement (male, 39).

Participants afraid to disclose their discordant relationship status and use of PrEP agreed that a person’s health status was between them and their partner. The main issue that undermined disclosure was HIV stigma, specifically anticipated stigma. While couples appeared to be able to navigate a positive test result with their partner, they did not believe that others would be as kind towards the HIV-positive partner’s status. One reported,

… many people are discriminated against for that disease [HIV] he [my husband] does not want anyone to know, because that family will also tell someone else, someone else will tell another, it will no longer be a secret to anyone (female, 29).

**Overcoming the fear of stigma to seek support from family and friends**

Participants who had not disclosed their discordant relationship status and use of PrEP to family and friends were concerned about how others would talk about and act towards them or their partner. One participant explained, ‘here in the field, when they know that the couple undergoes treatment … they just talk about it, so even if you were active [feeling well] you will start to be weak and demoralized’ (male, 39). Another agreed, describing how if, ‘someone also starts to know about it [our situation] you are very humiliated’ (female, 29).

Most participants who reported sharing their situation with family or friend(s) reported that it was a positive experience. Some participants told one family member or friend but were too afraid to tell others. One woman reported that her grandmother, ‘liked it [PrEP] because her granddaughter doesn’t have the disease [HIV]’ (female, 18). Others noted that family members stressed the importance of continuing to take PrEP, like one man, whose brother told him, ‘you cannot give up’ (male, 27). One man even reported that when his partner stopped taking her ART, her ‘sister came and counselled her and explained to her what the paths are and from there she started on her [antiretroviral] course till today’ (male, 38). When asked if they would recommend that others seek support from friends or family, one woman explained:

I was going to call only his closest family, parents, and siblings, because sometimes someone denies treatment not because they don’t want to, but because they are frustrated with the disease and need someone’s strength or advice (female, 38).

**Gendered adherence approaches**

There were differences in how female and male partners approached HIV treatment in their seropositive partner. Female partners reported pressuring their male partners to start PrEP and adhere to treatment, while male partners framed adherence as collaborative. Female participants tended to see themselves as the dominant force in health care seeking and treatment adherence. One reported that she, ‘tend[s] to force him [her partner] to take the medication … until I have the proof that he already took it, and he should also make me’ (female, 29). Another reported,

I was the one who forced my husband to come to the hospital for a test. He didn’t want [to] and I didn’t even know that there was a PrEP treatment so for both of us it was a great victory to know that he will be much better and I will be protected from the HIV virus (female, 37).

One man, aware of this dynamic, reported, '[My wife] told me to always get up and not stop taking [PrEP]' while simultaneously expressing the solidarity he and his partner found in staying adherent to their medicines, 'for her to live, and for me to live too!' (male, 39). Another man said that it was his ‘wife who gave [him] the most strength’ (male, 22) and a third reported, ‘the main strength we have is that after dinner we both take [PrEP and ART together]’ (male, 35). This description of solidarity reflected the belief males shared that to succeed in their treatment, the couple must work together for the benefit of the family.

**Organizational/clinic factors affecting PrEP uptake**

**Welcoming clinicians**

Most participants spoke in positive terms about their interaction with health care workers, counsellors, and peer activists. Almost all participants were satisfied with the system in place to collect their medications at the health facility. They found it comforting to hear medical information from medical professionals; and they felt safe asking questions about PrEP and their partner’s HIV diagnosis at the health facility. One woman explained that the clinic room was ‘safe, they serve us well and we are respected’ (female, 38).
Supportive community health workers
Participants also highlighted the importance of support from community health workers. One reported, ‘Those activists who pass in the communities, help [me] understand some things . . . congratulated me . . . and gave me a lot of strength’ (male, 39). A woman described her positive experience with nurses who visited community members in their homes to provide information and answer their questions. Another woman concurred, explaining in response to a question about the best way to support serodiscordant couples,

There are those people in the neighborhoods giving advice to couples, they may be able to advise them to get along and do the treatment. Because those who pass by the houses to give advice have helped many couples . . . They know the tactics for talking to such [difficult] people and are very patient people (female, 32).

The creation of oral stories to help future discordant couples
The above responses guided the template for the three stories aimed to increase PrEP uptake and adherence in Zambézia province (Table 2). The first story is designed to empower the couple to remain in care and adhere to treatment by presenting the experience of a couple who successfully start and stay to their medication. The second story provides strategies to overcome stigma and anger from the couple’s extended family. The third story focuses on strategies to manage an unsupportive spouse, including support that is available at the health facility and within the community. Each story presents potential barriers to PrEP adherence from various levels of the socioecological model, and examples of how couples can use resources available at different levels to overcome those barriers.

Discussion
There are more than 30 studies assessing the impact of biobehavioral interventions among serodiscordant couples in sub-Saharan Africa [30]. These studies were designed to increase knowledge and develop psychological skills [30–32], encourage couples-based HIV testing and counseling [33,34], and promote PrEP and ART uptake [35–37]. Across these studies, male partner attitudes and behaviors have a significant impact on uptake of, and adherence to, medication among women [38–40]. Similarly, our participants indicated how essential their partner’s support was for their PrEP (and ART) adherence. Although most participants felt comfortable staying in a serodiscordant relationship, women taking PrEP felt that they needed to pressure their partner to adhere to his ART, whereas men taking PrEP saw themselves engaged in collaborative relationships that promoted medication adherence. Similar experiences have been reported by women in seroconcordant, HIV-positive, relationships [41]. Harnessing the power of the couple to support adherence to medication may therefore require different strategies directed towards women and men. For example, men can often exert more control of their partner’s ART adherence than women, making PrEP a lifeline for women with partners with poor adherence [40]. Interventions that address stigma would be more effective if directed towards women who report greater fear of disapproval from partners or the community [42–44]. Although, different approaches will need to be cognizant of gender-based power imbalances that may, at their extreme, manifest as interpersonal violence and decreased PrEP adherence among female partners [45].

There also appears to be a disconnect between the actual and presumed attitudes towards HIV and PrEP among people in the community. Despite positive experiences among those who disclosed their status, participants reported a strong fear of stigmatization or discrimination from their community, which is consistent with other studies [46–48]. Previous research has also found stigma associated with PrEP-use disclosure and PrEP’s association with HIV [49–51]. Our participants’ fear of stigma was generally focused on how their community viewed their partner’s HIV status, not their use of PrEP. This presents an opportunity to shape how PrEP is perceived through coordinated implementation strategies, such as our oral stories, that directly address anticipated stigma among people living with HIV and within communities. Developing and delivering engaging stories has proved successful for several reasons: (1) Stories act as mnemonic devices for facts [52,53]; (2) Stories engage emotions, resulting in increased empathy and adoption of messages [54]; and (3) Stories that engage participants lead to story-consistent beliefs [55]. Given the history of oral storytelling as education in Mozambique, this culturally-informed tradition can be used to reduce HIV stigma and increase understanding of complex topics like PrEP and ART use [27–29].

Finally, interviewed couples suggested expanding the use of HIV community health agents to PrEP treatment support. Peer supporter programs, like similar ART programs, could result in decreased internalized stigma as well as increased knowledge and confidence in a client’s ability to take their medication regularly [16,17,56]. This strategy could help serodiscordant partners make well-informed decisions for themselves and their families in similar communities and further normalize HIV and intra-couple discordance, which would improve PrEP uptake and decrease PrEP-related stigma and HIV transmission. Community health agent
involvement can also expand the use of storytelling. Given low education levels in most rural areas in Mozambique, telling stories engages those taking medication and, if the couple is willing, their family. Given the importance of social support for long-term treatment adherence [57–59], family engagement in listening and responding to stories about ART and PrEP use among couples can provide an additional level of support for discordant couples.

**Methodologic considerations**

The results of this qualitative study are from one study site in rural Mozambique and may not transfer to perspectives in urban regions of Mozambique where PrEP knowledge is higher and attitudes towards PrEP may have already been established. Except for three participants, we did not capture the opinions of people who initiated PrEP but discontinued medication or those who were eligible but decided not to enroll in treatment. The general themes from this study, however, which align with other research in the field and were consistent among participants, will allow us to develop, test, replicate, and expand interventions to increase PrEP more broadly in rural Mozambique. Once we develop messaging and study its implementation among other community members, we will be in a better position to explore why some serodiscordant couples are not using PrEP, which we can then integrate into future interventions aimed at increasing PrEP uptake.

**Next steps**

We have integrated participant responses into three oral stories that will be delivered to serodiscordant couples, and if acceptable, their family. These stories target the individual, interpersonal, and organization levels of the socioecological model to increase PrEP uptake and reduce HIV transmission. A theatre-trained couple will present these stories to 35 randomly selected discordant couples at treatment initiation, two weeks, and one-month post enrollment. We will compare adherence to PrEP among this intervention group with those in standard of care. This will allow us to assess the efficacy of these stories, make modifications as appropriate, and implement similar story-driven interventions at other sites in rural Mozambique (Clinical Trial NCT04071470).

**Conclusions**

Policies aimed at increasing PrEP uptake in communities must engage serodiscordant partners and train community health agents to disseminate comprehensive information beyond clinic walls. These measures will likely allow rural health systems to increase PrEP uptake and reduce HIV transmission. Future studies should assess PrEP messaging and determine how it impacts PrEP uptake in different communities, given the need to reduce HIV transmission across Mozambique and beyond.

**Acknowledgments**

We would like to thank the participants for donating their time and effort to share their experiences and opinions on pre-exposure prophylaxis and our two interviewers who were able to create a comfortable environment for people to discuss PrEP and HIV freely.

**Disclosure statement**

The authors declare they have no competing interests.

**Ethics and consent**

This study was approved by the Vanderbilt University Medical Center (VUMC) Institutional Review Board (IRB #191472) and the Institutional Research Ethics Committee for Health of Zambézia (Comité Institucional de Bioética para Saúde – Zambézia 60/CIBS-Z/19). All participants provided written informed consent after the consent form and contents had been read aloud and explained in their language of preference, Portuguese or Echuabo.

**Funding information**

This work is supported by the National Institute of Mental Health grants [R01MH113478], CMA is also supported by [K01MH107255]. Research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number [F30MH123219] and by NIGMS of the National Institutes of Health under award number [T32GM007347 (DES)]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Author contributions**

CDS, EG, PP, AME, AM, CLF, SVR, and CMA designed the study, CDS, PP, EG, CLF, AME, AM, and AUA trained the interviewers. PP and CLF supervised data collection. DES and CMA conducted the data analysis. DES and CMA wrote the first draft of the manuscript. All authors edited and signed off on the final version of the manuscript.

**Paper context**

Pre-Exposure Prophylaxis (PrEP) is an essential component in stemming the HIV epidemic globally, however, PrEP uptake in sub-Saharan Africa is suboptimal. This paper elicits individuals in serodiscordant partnerships’ opinions about facilitators of and barriers to PrEP use in rural Mozambique. Their answers have helped guide educational materials for clinics in the region, which will be studied further prior to implementation in other regions in Mozambique.
References

[1] Cori A, Ayles H, Beyers N, et al. HPTN 071 PopART Study Team. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PloS One. 2014;9:e84511.

[2] Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245.

[3] World Health Organization. WHO | guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV [Internet]. Geneva, Switzerland: World Health Organization; 2012 Jul [cited 2020 Apr 27]. Available from: https://www.who.int/hiv/pub/guidance_prep/en/

[4] UNAIDS. HIV prevention 2020 road map — accelerating HIV prevention to reduce new infections by 75% [Internet]. Geneva, Switzerland; 2016; p. 36. Available from: https://www.unaids.org/sites/default/files/media_asset/hiv-prevention-2020-road-map_en.pdf

[5] Burns DN, Grossman C, Turpin J, et al. Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies. Curr HIV/AIDS Rep. 2014 Dec 1;11:393–403.

[6] Hanscom B, Janes HE, Guarino PD, et al. Preventing HIV-1 infection in women using oral pre-exposure prophylaxis: a meta-analysis of current evidence. J Acquir Immune Defic Syndr 1999. 2016 Dec 15;73:606–608.

[7] Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV-1 prevention among heterosexual men and women. N Engl J Med. 2012 Aug 2;367:399–410.

[8] Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012 Aug 2;367:423–434.

[9] Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Lond Engl. 2013 Jun 15;381:2083–2090.

[10] Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African Women. N Engl J Med. 2015 Feb 5;372:509–518.

[11] Van Damme L, Cornelis A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African Women. N Engl J Med. 2012 Aug 2;367:411–422.

[12] Bellan SE, Fiorella KJ, Melesse DY, et al. Extra-couple HIV transmission in sub-Saharan Africa: a mathematical modelling study of survey data. Lancet. 2013 May 4;381:1561–1569.

[13] Chemaitelly H, Awad SF, Abu-Raddad LJ. The risk of HIV transmission within HIV-1 sero-discordant couples appears to vary across sub-Saharan Africa. Epidemics. 2014 Mar 1;6:1–9.

[14] Tabana H, Doherty T, Rubenson B, et al. ‘Testing together challenges the relationship’: consequences of HIV testing as a couple in a high HIV prevalence setting in rural South Africa. PLoS ONE [Internet]. 2013 Jun 18 [cited 2020 Apr 27];8:e66390. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688905/

[15] Bunnell RE, Nassozi J, Muram E, et al. Living with discordance: knowledge, challenges, and prevention strategies of HIV-discordant couples in Uganda. AIDS Care. 2005 Nov 1;17:999–1012.

[16] Ahmed N, Pike C, Bekker L-G. Scaling up pre-exposure prophylaxis in sub-Saharan Africa. Curr Opin Infect Dis. 2019 Feb;32:24–30.

[17] Mugo NR, Ngure K, Kiragu M, et al. PrEP for Africa: what we have learnt and what is needed to move to program implementation. Curr Opin HIV AIDS. 2016 Jan;11:80–86.

[18] Pepfar ICAP. Avaliação do piloto da implementação da PrEP na Zâmbia, 2019. Zâmbia Province, Mozambique; 2020; Feb; p. 10

[19] IA M. Inquérito de Indicadores de Imunização, Malária e HIV/SIDA em Moçambique (IMASIDA 2015). Maputo: INSA; 2017.

[20] Moon TD, Blevins M, Green AF, et al. A: improving the health and livelihoods of children, women and families in the Province of Zambézia, Republic of Mozambique [Internet]. Nashville, TN: Vanderbilt University; 2015 [cited 2020 Apr 27]. Available from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.738.6190&rep=rep1&type=pdf

[21] National Institute of Statistics (INE). Mozambique. Mozambique population and housing census 2017 [Internet]. Mozambique: National Institute of Statistics (INE); 2017. Available from: http://www.ine.gov.mz/operacoes-estatisticas/censos/censo-2007/censo-2017/divulgacao-de-resultados-preliminares-do-iv-rgph-2017.pdf/view

[22] Guest G, Bunce A, Johnson L. How many interviews are enough?: an experiment with data saturation and variability. Field Methods. 2006 Feb;18:59–82.

[23] Bronfenbrenner U. Toward an experimental ecology of human development. Am Psychol. 1977;32:513–531.

[24] Haberer JE, Bangsberg DR, Baeten JM, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS Lond Engl. 2015 Jul 17;29:1277–1285.

[25] Wingood GM, Rubusto A, DiClemente RJ, et al. A new paradigm for optimizing HIV intervention synergy the role of interdependence in integrating HIV prevention interventions. J Acquir Immune Defic Syndr 1999. 2013 Jun;63:S108–13.

[26] Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.

[27] Zeelen J, Wijbenga H, Vintges M, et al. Beyond silence and rumor: storytelling as an educational tool to reduce the stigma around HIV/AIDS in South Africa. Healthc Educ. 2010 Jan 1;110:382–398.

[28] Tobin PKJ, Smyrna R. Once upon a time in Africa: a case study of storytelling for knowledge sharing. Aslib Proc New Inf Perspect. 2008 Mar 21;60:130–142.
Fatti G, Shaikh N, Jackson D, et al. Low HIV incidence in pregnant and postpartum women receiving a community-based combination HIV prevention intervention in a high HIV incidence setting in South Africa. PLOS ONE. 2017 Jul 27;12:e0181691.

Morton JF, Celum C, Njoroge J, et al. Counseling framework for HIV-serodiscordant couples on the integrated use of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention. J Acquir Immune Defic Syndr 1999. 2017 Jan 1;74:515–22.

Medley A, Baggaley R, Bachanas P, et al. Maximizing the impact of HIV prevention efforts: interventions for couples. AIDS Care. 2013;25:1569–1580.

Hatcher AM, Darbes L, Kvena Z, et al. Pathways for HIV prevention behaviors following a home-based couples intervention for pregnant women and male partners in Kenya. AIDS Behav. 2020 Jul 1;24:2091–2100.

Heffron R, Ngure K, Velloza J, et al. Implementation of a comprehensive safer conception intervention for HIV-serodiscordant couples in Kenya: uptake, use and effectiveness. J Int AIDS Soc. 2019;22:e25261.

Musinguzi N, Kidoguchi L, Mugo NR, et al. Adherence to recommendations for ART and targeted PrEP use among HIV serodiscordant couples in East Africa: the "PrEP as a bridge to ART" strategy. BMC Public Health. 2020 Oct 28;20:1621.

Muessig KE, Cohen MS. Advances in HIV prevention for serodiscordant couples. Curr HIV/AIDS Rep. 2014 Dec;11:434–446.

Skovdal M, Campbell C, Nyamukapa C, et al. When masculinity interferes with women’s treatment of HIV infection: a qualitative study about adherence to antiretroviral therapy in Zimbabwe. J Int AIDS Soc. 2011 Jun 9;14:29.

Conroy A, Leddy A, Johnson M, et al. ‘I told her this is your life’: relationship dynamics, partner support and adherence to antiretroviral therapy among South African couples. Cult Health Sex. 2017 Nov 2;19:1239–1253.

Gilbert HN, Wyatt MA, Pisarski EE, et al. PrEP discontinuation and prevention-effective adherence: experiences of PrEP users in Ugandan HIV serodiscordant couples. JAIDS J Acquir Immune Defic Syndr. 2019 Nov 1;82:265–274.

Bhagwanjee A, Govender K, Reardon C, et al. Gendered constructions of the impact of HIV and AIDS in the context of the HIV-positive seroconcordant heterosexual relationship. J Int AIDS Soc [Internet]. 2013 May 15 [cited 2021 Mar 8];16:18021. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656196/

Corneli A, Perry B, McKenna K, et al. Participants’ explanations for nonadherence in the PEM-PrEP clinical trial. JAIDS J Acquir Immune Defic Syndr. 2016 Apr 1;71:452–461.

Pintye J, Beima-Sofie KM, Makabong’O PA, et al. HIV-uninfected Kenyan adolescent and young women share perspectives on using pre-exposure prophylaxis during pregnancy. AIDS Patient Care STDs. 2018 Dec;32:538–544.

Camlin CS, Koss CA, Getahun M, et al. Understanding demand for PrEP and early experiences of PrEP use among young adults in rural Kenya and Uganda: a qualitative study. AIDS Behav. 2020 Jan 18;24:2149–2162.

Roberts ST, Haberer J, Celum C, et al. Intimate partner violence and adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV serodiscordant relationships: a prospective cohort study. J Acquir Immune Defic Syndr 1999. 2016 Nov 1;73:313–322.

Chan BT, Tsai AC. HIV stigma trends in the general population during antiretroviral treatment expansion: analysis of 31 countries in sub-Saharan Africa, 2003–2013. JAIMS J Acquir Immune Defic Syndr. 2016 Aug 15;72:558–564.

Chan BT, Maughan-Brown BG, Bogart LM, et al. Trajectories of HIV-related internalized stigma and disclosure concerns among ART initiators and non-initiators in South Africa. Stigma Health. 2019 Nov;4:433–441.

Ashaba S, Cooper-Vince C, Vofechovská D, et al. Community beliefs, HIV stigma, and depression among adolescents living with HIV in rural Uganda. Afr J AIDS Res AJAR. 2019 Sep;18:169–180.

Velloza J, Khoza N, Scorgie F, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020 Mar;23:e25463.

Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018 Apr;15:190–197.

Eakle R, Weatherburn P, Bourne A. Understanding users’ preferences of and preferences for oral PrEP for HIV prevention in the context of intervention scale-up: a synthesis of evidence from sub-Saharan Africa. J Int AIDS Soc [Internet]. 2019 Jul 22 [cited 2020 May 19];22. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643067/

Gucciardi E, Jean-Pierre N, Karam G, et al. Designing and delivering facilitated storytelling interventions for chronic disease self-management: a scoping review. BMC Health Serv Res. 2016 Jul 11;16:249.

McCabe JA. Integrating mnemonics into psychology instruction [Internet]. Baltimore, MD: Goucher College. 2011. Available from: http://teachpsych.org/resources/Documents/otrp/resources/mccabe11.pdf

Johnson DR, Huffman BL, Jasper DM. Changing race boundary perception by reading narrative fiction. Basic Appl Soc Psychol. 2014 Jan 1;36:83–90.

Green MC, Brock TC. The role of transportation in the persuasiveness of public narratives. J Pers Soc Psychol. 2000 Nov;79:701–721.

O’Malley G, Barnabee G, Mwgunya K. Scaling-up PrEP delivery in Sub-Saharan Africa: what can we learn from the scale-up of ART? Curr HIV/AIDS Rep. 2019;16:141–150.

Ncama BP, McNerney PA, Bhengu BR, et al. Social support and medication adherence in HIV disease in KwaZulu-Natal, South Africa. Int J Nurs Stud. 2008 Dec;45:1757–1763.

Yehia BR, Stewart L, Monplaisir F, et al. Barriers and facilitators to patient retention in HIV care. BMC Infect Dis. 2015 Dec;15:1–10.

Roy M, Czaicki N, Holmes C, et al. Understanding sustained retention in HIV/AIDS care and treatment: a synthetic review. Curr HIV/AIDS Rep. 2016 Jun;13:177–185.